A recent phase3 trial comparing tirzepatide vs semaglutide in people living with obesity (without diabetes) reported average weight loss of 20.2% with tirzepatide vs 13.7% with semaglutide over 72 weeks
If you develop severe, painful, or cystic acne that does not respond to initial self-care measures, contact your GP or the healthcare professional who prescribed Saxenda
Using the energy gap to address obesity: a commentary
The region benefits from advanced diagnostic capabilities, strong clinical awareness among healthcare providers, and robust reimbursement systems, which contribute to a higher uptake of GLP-1 therapies
(Cancer Genome Atlas Network) (June 2015)
Possible Side Effects: Mild (Common): Nausea, bloating, mild stomach discomfort